TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04958785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study: NCT04837417

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathologic group
Description: Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s.
Study: NCT05900115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Ready Parent
Description: The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Program
Description: The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
Study: NCT05590572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: (1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: (1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: (1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isophosphamide
Description: (1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isophosphamide
Description: (1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
Study: NCT04892563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Nerve block with local anesthetic in the erector spinae plane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Analgesia
Description: IV analgesia, typically Morphine/Opioid medications
Study: NCT05850741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiokit
Description: The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
Study: NCT06541444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
Study: NCT05589142

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time Restricted Eating
Description: Eating calories only during a specific feeding window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Eating calories only during a specific feeding window.
Study: NCT06179901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrative Korean Medicine Treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrative Korean Medicine Treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower limb motion style acupuncture treatment
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
Study: NCT06051630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine intravenous
Description: Perioperative lidocaine intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Serum saline intravenous
Description: Perioperative serum saline intravenous administration
Study: NCT04186260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAFLD-specific weight loss intervention
Description: This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.
Study: NCT06181071

Intervention type: OTHER
Group type: OTHER
Intervention: Distal Muscle Fatigue Protocol
Description: Initially, sociodemographic data, muscle viscoelastic properties, foot plantar pressure, and static and dynamic balance are assessed. Additionally, the strengths of the plantar flexor and dorsiflexor muscles are evaluated. After these assessments, the heel raise exercise will be implemented in this protocol. Firstly, dominant leg, the heel raise exercise will be performed for 3 sets with the knees in full extension until the individual reaches fatigue. Subsequently, the heel raise exercise will be conducted for another 3 sets with the knee in flexion until the individual reaches fatigue. Following these exercises, Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
Study: NCT05706792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordic Sensi Chair
Description: The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
Study: NCT05267626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-007
Description: Monoclonal Antibody Targeting IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-007
Description: Monoclonal Antibody Targeting IL-2
Study: NCT05225597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracameral administration of epinephrine and carbachol during cataract surgery
Description: All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracameral administration of epinephrine and carbachol during cataract surgery
Description: All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
Study: NCT05566860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positional Therapy
Description: After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positional Therapy
Description: After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positional Therapy
Description: After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral Negative Pressure Therapy
Description: If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral Negative Pressure Therapy
Description: If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral Negative Pressure Therapy
Description: If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
Study: NCT05267626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-007
Description: Monoclonal Antibody Targeting IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-007
Description: Monoclonal Antibody Targeting IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2
Study: NCT05267626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal Antibody Targeting PD-L1
Study: NCT05566860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Muscle Strength Training
Description: If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Muscle Strength Training
Description: If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
Study: NCT05473091

Intervention type: OTHER
Intervention: no intervention
Description: retrospective analysis
Study: NCT05668520

Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system
Description: Consent Paperwork~* Nutritional assessment using MNA and MUST questionnaires~* 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference

Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system
Description: Consent Paperwork~* Nutritional assessment using MNA and MUST questionnaires~* 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference
Study: NCT00512421

Intervention type: PROCEDURE
Intervention: computer-assisted surgery

Intervention type: PROCEDURE
Intervention: computer-assisted surgery
Study: NCT05375604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK-004
Description: ASO-STAT6 exosome administered Intravenously
Study: NCT05832775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRx0029
Description: Megasphaera massiliensis MRx0029 (Treatment A) and Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRx0029
Description: Megasphaera massiliensis MRx0029 (Treatment A) and Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRx0005
Description: Parabacteroides distasonis MRx0005 (Treatment B) and Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRx0005
Description: Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
Study: NCT06237192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab for B-ALL, venetoclax for T-ALL
Description: MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
Study: NCT06210932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social, Emotional, and Ethical Development (SEED) curriculum videos
Description: In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
Study: NCT05724043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartJournal
Description: SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
Study: NCT05617495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + fMRI Neurofeedback
Description: Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + fMRI Neurofeedback
Description: Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
Study: NCT05313776

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
Study: NCT05756192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
Study: NCT05858463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modality of exercise training
Description: muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modality of exercise training
Description: muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
Study: NCT04414917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twin block
Description: Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iPill dispenser
Description: An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPill dispenser
Description: An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).